Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Mirum Pharmaceuticals, Inc. - common stock
(NQ:
MIRM
)
74.46
-1.10 (-1.46%)
Streaming Delayed Price
Updated: 12:48 PM EST, Jan 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mirum Pharmaceuticals, Inc. - common stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
5 Predictions for the Stock Market in 2026 -- and Which Stocks Will Soar the Most If They're Right
↗
January 04, 2026
Not all of these predictions may come true. But at least a few of them will likely do so.
Via
The Motley Fool
Topics
Artificial Intelligence
Economy
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Shows Strong Growth Momentum and Bullish Technical Setup
↗
January 01, 2026
Via
Chartmill
Prediction: 3 Stocks That Will Be Worth More Than Newsmax 5 Years From Now
↗
December 30, 2025
These predictions were easy.
Via
The Motley Fool
Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line
↗
December 28, 2025
Selling shares usually signals doubt, but in this case the math points to something very different happening beneath the surface.
Via
The Motley Fool
Topics
Regulatory Compliance
Mirum Stock Slips On $820M Bluejay Deal — But Wall Street Calls The Hepatitis Drug Seal A 'Steal'
↗
December 08, 2025
Via
Stocktwits
Earnings Scheduled For November 4, 2025
↗
November 04, 2025
Via
Benzinga
Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX
December 19, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 10, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease
December 08, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Prediction: This Stock Has Soared Nearly 70% in 2025 and Will Be an Even Bigger Winner in 2026
↗
December 03, 2025
Mirum Pharmaceuticals is a mid-cap biotech stock to keep your eyes on.
Via
The Motley Fool
Topics
Earnings
Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake?
↗
December 02, 2025
A top life sciences investor is doubling down as Aurinia’s flagship therapy gains momentum—here’s what long-term shareholders should watch next.
Via
The Motley Fool
Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome
December 01, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Shows Strong Growth Momentum and Bullish Technical Setup
↗
November 29, 2025
Discover MIRM stock: A high-growth biotech with accelerating earnings, strong revenue, and a bullish technical setup poised for a potential breakout.
Via
Chartmill
Private Equity-Style Fund Buys $15.7 Million in Harrow Stock as Revenue Jumps 45%
↗
November 27, 2025
Harrow’s accelerating revenue and expanding product portfolio may help explain why a fundamentals-focused investment firm just made it a new position.
Via
The Motley Fool
Topics
Regulatory Compliance
Why This Private Equity-Style Fund Just Bet $17 Million on Lumen Technologies Stock
↗
November 27, 2025
One small-cap specialist just made a surprisingly large bet on one of telecom’s most complicated turnarounds.
Via
The Motley Fool
Penn Capital Unwinds $17.1 Million BGC Stake as Broker Posts 31% Revenue Surge
↗
November 27, 2025
This private-equity-style shop trimmed its position in a financial technology firm that's posting record numbers despite a steep stock decline.
Via
The Motley Fool
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
November 25, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD’s The Liver Meeting®
November 07, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
What Analysts Are Saying About Mirum Pharmaceuticals Stock
↗
November 05, 2025
Via
Benzinga
Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
November 04, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
November 03, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
October 28, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Presents a Compelling Growth Momentum and Technical Setup
↗
October 18, 2025
Mirum Pharmaceuticals (MIRM) shows strong revenue growth and a positive technical setup, presenting a compelling case for momentum investors seeking breakout opportunities.
Via
Chartmill
8 Analysts Assess Mirum Pharmaceuticals: What You Need To Know
↗
October 16, 2025
Via
Benzinga
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Combines Strong Growth Momentum with Bullish Technical Setup
↗
September 27, 2025
Mirum Pharmaceuticals (MIRM) shows strong growth momentum with accelerating revenue and earnings, combined with a top-rated technical setup suggesting a potential breakout.
Via
Chartmill
This Riot Platforms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
↗
September 24, 2025
Via
Benzinga
Demystifying Mirum Pharmaceuticals: Insights From 6 Analyst Reviews
↗
September 12, 2025
Via
Benzinga
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 10, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
